Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

LEO Pharma Gets EU Go-Ahead For Psoriasis Latecomer Brodalumab

Executive Summary

The Danish speciality dermatology company LEO Pharma has achieved a key plank in its plans to provide products for the range of psoriasis patients with an EU go-ahead for brodalumab.

You may also be interested in...



AAD Roundup: Sun Sets Sights On Psoriasis As Competitive Pressures Mount

Sun presented new data on its IL-23 inhibitor tildrakizumab, pending US FDA approval, at the American Academy of Dermatology meeting. Novartis and others – all competing for payers' dollars – also try to make the case for their products.

Reducing The Pain Of Skin R&D: Almirall And Leo Collaborate

Two European companies with portfolios in skin conditions have taken their first collaborative steps, researching non-painful skin sampling.

Sun Chief Sees ‘New Normal’ For First-To-File ANDAs Amid US Price Pressure

Sun Pharmaceutical Industries reported weak fourth quarter earnings amid US pricing pressure and the management has signaled a challenging FY2018 in store.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC098777

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel